Claris Lifesciences to sell its global generic injectables business to Baxter for $625 million

16 Dec 2016 Evaluate

Claris Lifesciences has entered into definitive agreements with Baxter International Inc. (Baxter) for the sale of its global generic injectables business for a total gross consideration of $625 million. The injectables business has been growing rapidly over the last few years and has attracted significant interest. The company intends to repatriate a significant majority of the net cash proceeds (post taxes and expenses) to the shareholders.

Credit Suisse and Jefferies acted as the financial advisers to Claris, Herbert Smith Freehills LLP, Veritas and AZB acted as the legal advisor to Claris.

Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly- owned subsidiary dealing in Speciality Injectables business and has a minority stake in Claris Otsuka. Claris has a total of 11 approved products in the US, around 25 ANDAs under review with the FDA and markets its products in 75+ countries.

Peers
Company Name CMP
Redington 263.55
Adani Enterprises 2156.70
Amrapali Industries 14.50
Rashi Peripheral 368.00
PDS 347.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×